These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10213207)

  • 21. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases.
    Schefter TE; Kavanagh BD; Timmerman RD; Cardenes HR; Baron A; Gaspar LE
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1371-8. PubMed ID: 16029795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
    Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
    Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.
    Ramnath N; Schwartz GN; Smith P; Bong D; Kanter P; Berdzik J; Creaven PJ
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):227-30. PubMed ID: 12655441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
    Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
    Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
    Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
    J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
    Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
    J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel radiation sensitizers targeting tissue hypoxia.
    Rowinsky EK
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):61-70. PubMed ID: 10550828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
    Berkenblit A; Eder JP; Ryan DP; Seiden MV; Tatsuta N; Sherman ML; Dahl TA; Dezube BJ; Supko JG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):584-90. PubMed ID: 17255281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
    Vink SR; Schellens JH; Beijnen JH; Sindermann H; Engel J; Dubbelman R; Moppi G; Hillebrand MJ; Bartelink H; Verheij M
    Radiother Oncol; 2006 Aug; 80(2):207-13. PubMed ID: 16914220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
    Ford JM; Seiferheld W; Alger JR; Wu G; Endicott TJ; Mehta M; Curran W; Phan SC
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):831-8. PubMed ID: 17560737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
    Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
    Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metalloporphyrin enhancement of magnetic resonance imaging of human tumor xenografts in nude mice.
    Furmanski P; Longley C
    Cancer Res; 1988 Aug; 48(16):4604-10. PubMed ID: 3396012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
    Ramanathan RK; Fakih M; Mani S; Deutsch M; Perez RP; Ritter MA; Eiseman JL; Ivy SP; Trump DL; Belani CP; Parise RA; Potter DM; Egorin MJ
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):465-74. PubMed ID: 16133531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI.
    Young SW; Qing F; Harriman A; Sessler JL; Dow WC; Mody TD; Hemmi GW; Hao Y; Miller RA
    Proc Natl Acad Sci U S A; 1996 Jun; 93(13):6610-5. PubMed ID: 8692865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myoglobin-loaded gadolinium nanotexaphyrins for oxygen synergy and imaging-guided radiosensitization therapy.
    Ma X; Liang X; Yao M; Gao Y; Luo Q; Li X; Yu Y; Sun Y; Cheng MHY; Chen J; Zheng G; Shi J; Wang F
    Nat Commun; 2023 Oct; 14(1):6187. PubMed ID: 37794000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.